ConductScience.org, home

Comparison · NCT02139306-24da7785

Ataluren vs Placebo: Number of Participants With Abnormal Vital Signs Reported as TEAEs

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Ataluren vs Placebo: Number of Participants With Abnormal Vital Signs Reported as TEAEs. Trial comparisons, record NCT02139306-24da7785. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02139306-24da7785

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 100.000000000000000001730.0267wilson
Risk in group 20.007190.001270.0396wilson
Risk difference, group 1 minus group 2-0.00719-0.03960.0202newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one fewer participant with the outcome on Ataluren than on Placebo139from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Ataluren
Participants received ataluren as oral powder for suspension at the dosages of 10, 10, and 20-mg/kg at morning, midday and evening, respectively for 48 weeks of treatment duration or until treatment discontinuation.
0140OG000
Group 2PlaceboParticipants received matching placebo orally at morning, midday and evening for 48 weeks of treatment duration or until treatment discontinuation.1139OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Abnormal Vital Signs Reported as TEAEs
Description
Vital signs included systolic and diastolic blood pressure, pulse rate, pulse oximetry, and body temperature. Participants with abnormal vital signs who required clinical intervention or further investigation (beyond ordering a repeat \[confirmatory\] test) unless they are associated with an already reported clinical event are reported.
Time frame
From study drug administration to 4-week post treatment follow-up visit (approximately 52 weeks)
Population
The as-treated population included all randomized participants who actually received any study treatment.

Source ClinicalTrials.gov

Trial

Title
Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)
NCT number
NCT02139306
Phases
PHASE3
Conditions
Cystic Fibrosis
Interventions
Ataluren (PTC124®), Placebo
Lead sponsor
PTC Therapeutics
Results first posted
2020-05-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02139306-24da7785